Melanotan-1 vs PT-141

Melanotan-1

Melanotan 1, also designated Afamelanotide, is a linear synthetic tridecapeptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH) with the substitution of Nle at position 4 and D-Phe at position 7, conferring modulated receptor binding affinity and metabolic stability. Melanotan 1 selectively activates melanocortin-1 receptor (MC1R), the primary receptor responsible for melanogenesis in epidermal melanocytes. MC1R activation triggers adenylyl cyclase-mediated cAMP elevation, which upregulates microphthalmia-associated transcription factor (MITF) and downstream eumelanin synthesis enzymes. Research published in the British Journal of Dermatology by Barnetson et al. (2006) demonstrated that Afamelanotide produced significant increases in melanin density without UV exposure in fair-skinned individuals, conferring a measurable photoprotective effect. Harms et al. in Photochemistry and Photobiology showed that Melanotan 1-induced eumelanin production provided DNA damage protection equivalent to moderate constitutive pigmentation. Studies in erythropoietic protoporphyria (EPP) patients published in the New England Journal of Medicine (Langendonk et al., 2015) demonstrated that Afamelanotide significantly increased pain-free time in sunlight. Compared to Melanotan 2, which is a cyclic heptapeptide acting non-selectively across MC1R through MC5R, Melanotan 1 is more selective for MC1R and therefore produces fewer off-target effects. Melanotan 2 additionally activates MC4R (associated with appetite and arousal), while Melanotan 1's selectivity makes it more suitable for focused pigmentation research. Store lyophilized Melanotan 1 at -20°C, protected from light. Reconstitute with bacteriostatic water and store at 2-8°C, using within 4 weeks. This peptide is studied by dermatologists, photobiologists, and researchers investigating melanocortin receptor pharmacology and photoprotective strategies.

PT-141

PT-141, also known as Bremelanotide, is a cyclic heptapeptide melanocortin receptor agonist derived from the alpha-melanocyte-stimulating hormone (alpha-MSH) analogue Melanotan II. Unlike PDE5 inhibitors that act on vascular smooth muscle, PT-141 operates centrally through melanocortin-4 receptor (MC4R) activation in the hypothalamus and limbic system, initiating downstream dopaminergic signaling pathways associated with arousal and sexual motivation. Phase III clinical trials conducted by Palatin Technologies and published in The Journal of Sexual Medicine demonstrated that PT-141 use produced statistically significant increases in satisfying sexual events and desire scores in premenopausal women with hypoactive sexual desire disorder (HSDD). Research by Diamond et al. (2006) in the International Journal of Impotence Research showed efficacy in male subjects who had not responded to PDE5 inhibitor therapy, suggesting a fundamentally different mechanism of action. Additional preclinical studies have identified potential roles in hemorrhagic shock models, where MC receptor activation provided protective effects on organ perfusion. Compared to sildenafil (Viagra) and tadalafil (Cialis), which are peripherally acting vasodilators, PT-141 is unique in its central nervous system mechanism. This distinction is significant because it suggests PT-141 may address desire-based dysfunction rather than purely mechanical melanocortin-pathway signaling. Melanotan II, its parent compound, activates multiple MC receptors non-selectively, while PT-141 shows preferential MC4R and MC1R activity. Store lyophilized PT-141 at -20°C. Reconstitute with bacteriostatic water and keep at 2-8°C, using within 4 weeks. PT-141 is investigated by sexual medicine researchers, neuroendocrinologists, and emergency medicine scientists studying melanocortin-based interventions.

Frequently Asked Questions